Determination of tamoxifen-DNA adducts in leukocytes from breast cancer patients treated with tamoxifen

Chemical Research in Toxicology

Volumn 17, Issue 12, 2004, Pages 1577-1583

  Umemoto, Atsushi ^a   Monden, Yasumasa ^a   Lin, Chun Xing ^a   Momen, Md Abdul ^a   Ueyama, Yuji ^a   Komaki, Kansei ^a   Laxmi, Y R Santosh ^b   Shibutani, Shinya ^b  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA (N2 DEOXYGUANOSINYL)TAMOXIFEN 3' PHOSPHATE; ALPHA (N2 DEOXYGUANOSINYL)TAMOXIFEN N OXIDE 3' PHOSPHATE; ALPHA (N2 DEOXYGUANOSYL) N NORTAMOXIFEN 3' PHOSPHATE; NUCLEOTIDE; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; DIASTEREOISOMER; DNA ADDUCT; DNA DETERMINATION; ENDOMETRIUM CANCER; FEMALE; GENOTOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LEUKOCYTE; QUANTITATIVE ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA ADDUCTS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; LEUKOCYTES; MIDDLE AGED; STEREOISOMERISM; TAMOXIFEN;

EID: 10844288073     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx049930c     Document Type: Article

References (45)

1. Jordan, V. C. (1994) The development of tamoxifen for breast cancer therapy. In Long-Term Tamoxifen Treatment for Breast Cancer (Jordan, V. C., Ed.) pp 3-26, University of Wisconsin Press, Madison.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans (1996) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol. 66. Some Pharmaceutical Drugs, IARC Scientific Publications, Lyon.
3. Fisher, B., Constantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., Daly, M., Wieand, S., Tan-Chiu, E., Ford, L., and Wolmark, N. (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90, 1371-1388.
4. Powles, T., Eeles, R., Ashley, S., Easton, D., Chang, J., Dowsett, M., Tidy, A., Viggers, J., and Davey, J. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352, 98-101.
5. Rutqvist, L. E., Johansson, H., Signomklao, T., Johansson, U., Fornander, T., and Willing, N. (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignacies. Stockholm Breast Cancer Study Group. J. Natl Cancer Inst. 87, 645-651.
6. Gallo, M. A., and Kaufman, D. Antagonistic and agonistic effects of tamoxifen: Significance in human cancer (1997) Semin. Oncol. 24 (1 Suppl. 1), S1-71-S1-80.
7. Greaves, P., Goonetilleke, R., Nunn, G., Topham, J., and Orton, T. (1993) Two-year carcinogenecity study of tamoxifen in Alderley Park Wister-derived rats. Cancer Res. 53, 3919-3924.
8. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., and Williams, G. M. (1993) Major difference in the hepatocarcinogenecity and DNA adduct froming ability between toremifene and tamoxifen in female Crl:cD(BR) rats. Cancer Res. 53, 4534-4541.
9. Kuiper, G. G., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., and Gustafsson, J. A. (1997) Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138, 863-870.
10. Li, D., Dragan, Y., Jordan, V. C., Wang, M., and Pitot, H. C. (1997) Effects of chronic administration of tamoxifen and toremifene on DNA adducts in rat liver, kidney, and uterus. Cancer Res. 57, 1438-1441.
11. 2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res. 59, 2091-2095.
12. Davies, R., Gant, T. W., Smith, L. L., and Styles, J. A. (1999) Tamoxifen induces G:C→T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5′-CpG-3′ dinucleotide sequences as found in the lacI transgene. Carcinogenesis 20, 1351-1356.
13. da Costa, G. G., Manjanatha, M. G., Marques, M. M., and Beland, F. A. (2002) Induction of lacI mutations in Big Blue rats treated with tamoxifen and α-hydroxytamoxifen. Cancer Lett. 176, 37-45.
14. Otteneder, M., and Lutz, W. K. (1999) Correlation of DNA adduct levels with tumor incidence: carcinogenic potency of DNA adducts. Mutat. Res. 424, 237-247.
15. Bergman, L., Beelen, M. L., Gallee, M. P., Hollema, H., Benraadt, J., van Leeuwen, F. E., and the Comprehensive Cancer Centres' ALERT Group (2000) Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356, 881-887.
16. Hemminki, K., Rajaniemi, H., Lindahl, B., and Moberger, B. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 56, 4374-4377.
17. Hemminki, K., Rajaniemi, H., Koshinen, M., and Hansson, J. (1997) Tamoxifen-induced DNA adducts in leukocytes of breast cancer patients. Carcinogenesis 18, 9-13.
18. Orton, T. C., and Topham, J. C. (1997) Correspondence re: Hemminki, K. et al. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 56, 4374-4377. Cancer Res. 57, 4148.
19. Orton, T. C., and Topham, J. C. (1997) Correspondence re: Hemminki, K. et al. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 56, 4374-4377. Cancer Res. 57, 4148.
20. Phillips, D. H., Hewer, A., Grover, P. L., Poon, G. K., and Carmichael, P. L. (1996) Tamoxifen does not form detectable DNA adducts in white blood cells of breast cancer patients. Carcinogenesis 17, 1149-1152.
21. Carmichael, P. L., Ugwumadu, A. H. N., Neven, P., Hewer, A. J., Poon, G. K., and Phillips, D. H. (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res. 56, 1475-1479.
22. 32P-post-labeling for tamoxifen-DNA adducts in the human endometrium. Carcinogenesis 20, 339-342.
23. Osborne, M. R., Hewer, A., Davis, W., Strain, A. J., Keogh, A., Hardcastle, I. R., and Phillips, D. H. (1999) Idoxifene derivatives are less reactive to DNA than tamoxifen derivatives, both chemically and in human and rat liver cells. Carcinogenesis 20, 293-297.
24. Bartsch, H., Phillips, D. H., Nair, J., Hewer, A., Meyberg-Solomeyer, G., and Grischke, E. M. (2000) Lack of evidence for tamoxifen- and toremifene-DNA adducts in lymphocytes of treated patients. Carcinogenesis 21, 845-847.
25. Shibutani, S., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P., and Pearl, M. L. (1999) Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem. Res. Toxicol. 12, 646-653.
26. Shibutani, S., Ravindernath, A., Suzuki, N., Terashima, I., Sugarman, S. M., Grollman, A. P., and Pearl, M. L. (2000) Identification of tamoxifen-DNA adducts in the endometrium of women treated with tamoxifen. Carcinogenesis 21, 1461-1467.
27. Sharma, M., Shubert, D. E., Sharma, M., Lewis, J., McGarrigle, B. P., Bofinger, D. P., and Olson, J. R. (2003) Antioxidant inhibits tamoxifen-DNA adducts in endometrial explant culture. Biochem. Biophys. Res. Commun. 307, 157-164.
28. Shibutani, S., Suzuki, N., Laxmi, Y. R., Schild, L. J., Divi, R. L., Grollman, A. P., and Poirier, M. C. (2003) Identification of tamoxifen-DNA adducts in monkeys treated with tamoxifen. Cancer Res. 63, 4402-4406.
29. Schild, L. J., Divi, R. L., Beland, F. A., Churchwell, M. I., Doerge, D. R., Gamboa da Costa, G., Marques, M. M., and Poirier, M. C. (2003) Formation of tamoxifen-DNA adducts in multiple organs of adult female cynomolgus monkeys dosed with tamoxifen for 30 days. Cancer Res. 63, 5999-6003.
30. Umemoto, A., Kajikawa, A., Tanaka, M., Hamada, K., Seraj, M. J., Kubota, A., Nakamura, M., Kinouchi, T., Ohnishi, Y., Yamashita, K., and Monden, Y. (1994) Presence of mucosa-specific DNA adduct in human colon: possible implication for colorectal cancer. Carcinogenesis 15, 901-905.
31. Dasaradhi, L., and Shibutani, S. (1997) Identification of tamoxifen-DNA adducts formed by α-sulfate tamoxifen and α-acetoxytamoxifen. Chem. Res. Toxicol. 10, 189-196.
32. Umemoto, A., Monden, Y., Komaki, K., Suwa, M., Kanno, Y., Suzuki, M., Lin, C., Ueyama, Y., Momen, M. A., Ravindernath, A., and Shibutani, S. (1999) Tamoxifen-DNA adducts formed by α-acetoxytamoxifen N-oxide. Chem. Res. Toxicol. 12, 1083-1089.
33. 2- deoxyguanosinyl)tamoxifen N-oxide. Carcinogenesis 21, 1737-1744.
34. Kitagawa, M., Ravindernath, A., Suzuki, N., Rieger, R., Terashima, I., Umemoto, A., and Shibutani, S. (2000) Identification of tamoxifen-DNA adducts induced by α-acetoxy-N-desmethyltamoxifen. Chem. Res. Toxicol. 13, 761-769.
35. 32P-postlabeling test for structurally diverse DNA adducts. Carcinogenesis 7, 1543-1551.
36. Umemoto, A., Komaki, K., Monden, Y., Suwa, M., Kanno, Y., Kitagawa, M., Suzuki, M., Lin, C., Ueyama, Y., Momen, M. A., Ravindernath, A., and Shibutani, S. (2001) Identification and quantification of tamoxifen-DNA adducts in the liver of rats and mice. Chem. Res. Toxicol. 14, 1006-1013.
37. 32P-post-labeled DNA adducts by the development of a novel automated on-line solid-phase extraction HPLC method. Carcinogenesis 19, 1061-1069.
38. 32P-postlabeling analysis. Proc. Am. Assoc. Cancer Res. 43, 1042.
39. Sanchez, C., Shibutani, S., Dasaradhi, L., Bolton, J. L., Fan, P. W., and McClelland, R. A. (1998) Lifetime and reactivity of an ultimate tamoxifen carcinogen: The tamoxifen carbocation. J. Am. Chem. Soc. 120, 13513-13514.
40. Osborne, M. R., Hewer, A., Hardcastle, I. R., Carmichael, P. L., and Phillips, D. H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56, 66-71.
41. Shibutani, S., Dasaradhi, L., Terashima, I., Banoglu, E., and Duffel, M. W. (1998) α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res. 58, 647-653.
42. da Costa, G. G., McDaniel-Hamilton, L. P., Heflich, R. H., Marques, M. M., and Beland, F. A. (2001) DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis 22, 1307-1315.
43. Poon, G. K., Walter, B., Lønning, P. E., Horton, M. N., and McCague, R. (1995) Identification of tamoxifen metabolites in human HEP G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer. Drug Metab. Dispos. 23, 377-382.
44. Lien, E. A., Solheim, E., and Ueland, P. M. (1991) Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res. 51, 4837-4844.
45. Tang, D., Phillips, D. H., Stampfer, M., Mooney, L. A., Hsu, Y., Cho, S., Tsai, W. Y., Ma, J., Cole, K. J., She, M. N., and Perera, F. P. (2001) Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. Cancer Res. 61, 6708-6712.